The market of chemical API will promote the strength of upstream pharmaceutical intermediates

- Apr 19, 2018 -

So-called pharmaceutical intermediates are intermediate chemicals made in the process of chemical synthesis, often just one step to two steps to synthesize the drug and eventually make the finished product. Basic chemical raw materials are the upstream of pharmaceutical intermediates, and the raw materials and preparations are downstream of pharmaceutical intermediates. Basic chemical raw materials, pharmaceutical intermediates, apis and preparations constitute the complete industrial chain of chemical pharmaceutical industry.

Pharmaceutical intermediates industry in our country since the 1970 s, after more than 30 years of rapid development, China's pharmaceutical intermediates production basic can meet the demand of our country medicine production, only a few need to import, such as the need to introduce the GCLE complex synthesis technologies such as high-end intermediates. From 2008 to 2014, the total output value of pharmaceutical intermediates in China increased year by year. In particular, in 2013, the total output value of China's pharmaceutical intermediates industry was 349.0 billion yuan, a year-on-year increase of 13.89%. In 2014, the total output value of China's pharmaceutical intermediates industry was 384.552 billion yuan, up 10.16% year on year.

In China, the oversupply of pharmaceutical intermediates is prominent, and the dependence on exports is increasing. But China's exports are mainly concentrated in vitamin C, penicillin, acetaminophen, citric acid and its salts and esters, such as commodities, output the characteristics of the products is huge, production enterprises, the market competition is intense, product price and added value is low, the mass production of them caused the domestic pharmaceutical intermediates market oversupply situation. High-technology products still rely heavily on imports.

For the protection of amino acid pharmaceutical intermediates, most of the products in domestic production enterprises are single, and the quality is unstable, which is mainly customized for foreign biopharmaceuticals companies. Only some enterprises with strong research and development strength, advanced production facilities and large-scale production experience can obtain high profits in the competition.


Related Industry Knowledge

Related Products

  • Meldrumacid
  • 3-(2-Bromopropanoyl)spiro[benzo[e][1,3]oxazine-2,1'-cyclohexan]-4(3H)-one
  • 9,9-dimethylfluoren-2-amine
  • C15H15N
  • Fomesafen 72178-02-0
  • 5-[2-chloro-4-(trifluoromethyl) Phenoxy]-N-(methylsulfonyl) - 2-nitro-(72178-02-0)